Hancock Jaffe Announces January CoreoGraft Study at the Texas Heart Institute

Tailwinds' Take: There are currently no approved alternatives to vein harvesting and this study is the last step before applying to the FDA to...

What To Put In Your Stockings: December Preview

This weekend we'll be hanging our stockings on the mantel. Come Christmas morning, they'll be lying on the floor, overflowing with presents. At least,...

Hancock Jaffe Updates Status of Application to INVIMA for First-In-Human VenoValve Trial in Colombia

Tailwinds' Take: making progress towards first-in-man trials, which dates will be announced in December; we expect an early Q1 2019 launch of the trial....

Hancock Jaffe Appoints Chris Sarner as Vice President of Regulatory Affairs and Quality Assurance

IRVINE, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac...

Hancock Jaffe Shareholder Update Letter

Dear Hancock Jaffe Shareholders: Since joining Hancock Jaffe in April of 2018, this is the first occasion for me to address all of our shareholders...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

Texas Heart Takes To The CoreoGraft™

This week Hancock Jaffe Laboratories (HJLI) announced a partnership with the Texas Heart Insitute, a world-renowned leader in cardiovascular disease. This partnership, which is...

Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute

Tailwinds' Take: this is great news for their second product, the CoreoGraft. Texas Heart is a world class partner and the end market is...

Hancock Jaffe Appoints Three New Independent Directors

Tailwinds' Take: this is a great endorsement of the products and end markets that HJLI is targeting. The background of each new member is...

Hancock Jaffe Laboratories to Present at The MicroCap Conference on October 2, 2018 in...

IRVINE, Calif., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac...

Hancock Jaffe Submits Application to INVIMA for First-In-Human VenoValve Trial in Colombia

Tailwinds' Take: another step towards being the only FDA approved product for CVI, a multi-billion dollar indication. We believe that the likelihood of this...

New Study Confirms Significant Potential U.S. Market for Hancock Jaffe’s VenoValve

Tailwinds' Take: The VenoValve is progressing towards FDA approval. Once approved, the market size is huge. HJLI is significantly undervalued based on this research. IRVINE,...

Hancock Jaffe Laboratories’ VenoValve Featured in Journal of Vascular Surgery Venous and Lymphatic Disorders...

IRVINE, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac...

Counting Down To The VenoValve

With a market cap hovering around $25M, Hancock Jaffe Laboratories stock is severely discounting the success of any of its three products that are...

Catching Up With Hancock Jaffe and The VenoValve…

We had the opportunity to speak with Dr. Marc H. Glickman, the Chief Medical Officer at Hancock Jaffe (HJLI). During our conversation, we discussed...

Hancock Jaffe Laboratories Receives Medical Research Committee Approval for First-in-Human VenoValve Study

Tailwinds' Take: one step closer to first-in-man trials. HJLI is moving down three paths with unique products that could each be a company-maker. IRVINE, Calif.,...

Hancock Jaffe Laboratories Receives Ethics Committee Approval for First-in-Human VenoValve Study

Tailwinds' Take: another positive step towards an approved product. As what would be the only product in a multi-billion market, the VenoValve has the...

Hancock Jaffe Appoints Bob Rankin as Chief Financial Officer

Tailwinds' Take: with 3 product candidates moving down the pipeline, CEO Rob Berman continues to transform the Company in his vision, positioning them for...

Hancock Jaffe Laboratories to Conduct Analysis for FDA Submission Package for Bioprosthetic Heart Valve

Tailwinds' Take: Hancock Jaffe has the funding to get their 3 lead products in front of the FDA, each of which should be a...

The VenoValve is Hancock Jaffe’s Golden Ticket

When I last wrote about Hancock Jaffe (HJLI), the topic was how the weakness around their IPO created a buying opportunity for forward looking...